Skip to main content
. 2017 Mar 15;8(24):38294–38308. doi: 10.18632/oncotarget.16203

Figure 1. Docetaxel (DTX) induces CD24+/high to CD24−/low, or CD24−/low to CD24+/high transitions or no change of CD24 expression in BC cell lines, while doxorubicin (DXR) only induces CD24+/high to CD24−/low transitions.

Figure 1

(A) and (B) show Fluorescence-Activated Cell Sorting (FACS) results and the respective bar graphs. Error bars represent standard error of the mean (SEM). The p-values were calculated using an unpaired t test. *P < 0.05; ***P < 0.001. (A) The cells were treated with 6 μM docetaxel for 1 to 3 days and then stained with CD24-PE and CD44-FITC for FACS analysis. HCC1806, HCC1937 and HCC38 are TNBC cell lines. JIMT-1 is a HER2-overexpressing BC cell line. (B) HCC1806 and HCC1937 were treated with 4 μM doxorubicin for 1 to 3 days and then stained with CD24-Brilliant Violet 421 and CD44-FITC. (C) The summarized results of A and B.